Physician profile
William Casey Conner
NPI 1609068246
$818.26
in general payments reported to CMS, 2019-2025
11 companies · $70.02 in 2025
The $70.02 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $188 · 2021: $83.19 · 2022: $43.94 · 2023: $77.17 · 2024: $21.84 · 2025: $70.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.76 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $259.08 | 2019-2020 | |
| Corium, LLC | $144.24 | 2021-2025 | Azstarys, Azstarys |
| Pfizer INC. | $128.62 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $60.29 | 2019-2025 | Bexsero |
| Neos Therapeutics, Lp | $34.59 | 2019 | |
| Collegium Pharmaceutical, INC. | $33.36 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $31.60 | 2021-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $18.23 | 2019 | |
| Adlon Therapeutics L.P. | $16.69 | 2020 | |
| Sanofi Pasteur INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.